The aim of this study is to determine if circulating fatty acid-binding protein 4 (FABP4) plasma levels are a possible marker of metabolic risk in SLE patients. Circulating levels of adipose FABP4 are associated with adiposity, insulin resistance (IR), metabolic syndrome, diabetes and cardiovascular diseases. Patients affected by systemic lupus erythematosus (SLE) show an accelerated atherosclerosis that cannot be entirely explained by traditional cardiovascular risk factors. Sixty consecutive patients with SLE and 34 non-SLE age-matched controls were recruited for the study. Total plasma lipids and circulating FABP4 were determined. Subclinical atherosclerosis was evaluated by measuring carotid intimae-media thickness (c-IMT) by sonography, and the distribution of lipoprotein subclasses was analysed by nuclear magnetic resonance (NMR) spectroscopy. In the SLE group, FABP4 was associated with IR, atherogenic dyslipidaemia, as measured by NMR, and the presence of subclinical atherosclerosis. In multivariate analyses FABP4 was associated with increased c-IMT independent of the inflammatory state of the patient. In sum, circulating FABP4 is involved in the metabolic disturbances of SLE affecting lipid metabolism and IR, and it could be a biomarker of atherosclerosis in this population.
NossentJCikesNKissE. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: Relation to disease activity and damage accrual. Lupus2007; 16: 309–317.
2.
WardMM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum1999; 42: 338–346.
3.
Asanuma YuOeserAAyumiK. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med2003; 349: 2407–2415.
4.
SalmonJERomanMJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med2008; 121(10 Suppl 1): S3–S8.
5.
RomanMJCrowMKLockshinMD. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum2007; 56: 3412–3419.
6.
de CarvalhoJFBonfaEBorbaEF. Systemic lupus erythematosus and “lupus dyslipoproteinemia”. Autoimmun Rev2008; 7: 246–250.
7.
EsdaileJMAbrahamowiczMGrodzickyT. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum2001; 44: 2331–2337.
8.
SabioJMZamora-PasadasMJiménez-JáimezJ. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus2008; 17: 849–859.
9.
ChungCPAvalosIOeserA. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis2007; 66: 208–214.
10.
López-PedreraCAguirreMÁBarbarrojaNCuadradoMJ. Accelerated atherosclerosis in systemic lupus erythematosus: Role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol2010; 2010: 607084–607084.
11.
GoldbergRJUrowitzMBIbáñezDNikpourMGladmanDD. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol2009; 36: 2454–2461.
12.
ParraSVivesGFerréR. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients. Atherosclerosis2012; 225: 224–223.
13.
VadaccaMMargiottaDRigonA. Adipokines and systemic lupus erythematosus: Relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol2009; 36: 295–297.
14.
TellesRWLannaCCDFerreiraGARibeiroA. Metabolic syndrome in patients with systemic lupus erythematosus: Association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus2010; 19: 803–809.
15.
SabioJMVargas-HitosJZamora-PasadasM. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol2009; 36: 2204–2211.
16.
HuGQiaoQTuomilehtoJ. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med2004; 164: 1066–1076.
17.
LozovoyMABSimãoANCHohmannMS. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus2011; 20: 1356–1364.
18.
ChungCPLongAGSolusJF. Adipocytokines in systemic lupus erythematosus: Relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus2009; 18: 799–806.
19.
CaoHGerholdKMayersJRWiestMMWatkinsSMHotamisligilGS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell2008; 134: 933–944.
20.
MakowskiLBrittinghamKCReynoldsJMSuttlesJHotamisligilGS. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and Ikappa B kinase activities. J Biol Chem2005; 280: 12888–12895.
21.
XuAWangYXuJY. Adipocyte fatty acid binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem2006; 52: 405–413.
22.
MakowskiLHotamisligilGS. The role of fatty acid-binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol2005; 16: 543–548.
23.
ErbayEBabaevVRMayersJR. Reducing endoplasmatic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med2009; 15: 1383–1391.
24.
MakowskiLBoordJBMaedaK. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med2001; 7: 699–705.
25.
FuruhashiMFuchoRGorgunCZ. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest2008; 118: 2640–2650.
26.
LázaroIDíazMCabréAMasanaLIbáñezL. Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. Gynecol Endocrinol2011; 27: 935–939.
27.
CollBCabreAAlonso-VillaverdeC. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis2008; 199: 147–153.
28.
BagheriRQasimAMehtaNN. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol2010; 106: 1118–1123.
29.
HolmSUelandTDahlTB. Fatty acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke. PlosOne2011; 6: e28785–e28785.
30.
AgardhHEFolkersenLEkstrandJ. Expression of fatty-acid-binding protein aP2 is correlated with plaque instability in carotid atherosclerosis. J Intern Med2011; 269: 200–210.
31.
CabréALázaroIGironaJ. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res2008; 4: 1746–1751.
32.
CabréALázaroIGironaJ. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis2007; 195: e150–e158.
33.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1740.
34.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem1972; 18: 499–502.
35.
National Cholesterol Education Program. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA2001; 285: 2486–2497.
36.
EckelRHGrundySMZimmetPZ. The metabolic syndrome. Lancet2005; 365: 1415–1428.
37.
ReillyMPWolfeMLRhodesT. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation2004; 110: 803–809.
38.
GonzàlezMRibaltaJVivesG. Nuclear magnetic resonance lipoprotein subclasses and the APOE genotype influence carotid atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol2010; 37: 2259–2267.
39.
SteinJHKorcarzCEHurstRT. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr2008; 21: 93e111–93e111.
40.
JunyentMGilabertRNúñezI. Carotid ultrasound in the assessment of preclinical atherosclerosis. Distribution of intima-media thickness values and plaque frequency in a Spanish community cohort [article in Spanish]. Med Clin (Barc)2005; 125: 770–774.
41.
YeungDCXuACheungCW. Adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol2006; 27: 1796–1802.
42.
AragonèsGFerréRLázaroI. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis2010; 213: 329–331.
